

Docket No. REG 132B1-C

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**Applicants:** Economides et al.

US Serial No.: to be assigned

Group: to be assigned

Filing Date: Concurrently herewith

Examiner: to be assigned

Title: Therapeutic Method For Treating Bone Formation Diseases

**INFORMATION DISCLOSURE STATEMENT  
UNDER 37 CFR §§ 1.56 and 1.97**

Commissioner for Patents  
U.S. Patent & Trademark Office  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

In compliance with the Applicants' duty to submit information material to patentability of the above-referenced case, Applicants herein submit the following Information Disclosure Statement with the accompanying PTO Form 1449. The PTO is kindly requested to make of record those references which may be pertinent to the examination of the above-referenced application.

**REQUEST FOR TRANSFER OF REFERENCE COPIES**

- Applicants respectfully request that the cited references filed in the Information Disclosure Statement submitted in connection with parent application USSN 09/897,322, filed July 2, 2001, be transferred to the subject application for consideration by the Examiner.
- Copies of references cited by Examiner in parent case are attached.

**Fees**

No fee is required for the filing of this Information Disclosure Statement. If any additional fees should be deemed necessary, the Commissioner is hereby authorized to charge Deposit Account Number 18-0650.

Respectfully submitted

  
Valeta Gregg  
Reg. No. 35,127  
Regeneron Pharmaceuticals, Inc.  
777 Old Saw Mill River Road  
Tarrytown, New York 10591  
(914) 345-7400

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Applicants: Economides et al.

Serial No.: to be assigned Group: to be assigned

Filing Date: Concurrently herewith Examiner: to be assigned

Title: Therapeutic Method For Treating Bone Formation Diseases

## U.S. PATENT DOCUMENTS

| Examiner<br><u>Initials</u> | Patent<br><u>Number</u> | Issue<br><u>Date</u> | Publication<br><u>Number</u> | Publication<br><u>Date</u> | Name               |
|-----------------------------|-------------------------|----------------------|------------------------------|----------------------------|--------------------|
| _____                       | 5,030,576               | 7/9/91               |                              |                            | Dull, et al.       |
| _____                       | 4,857,637               | 8/15/89              |                              |                            | Hammonds, et al.   |
| _____                       | 4,933,294               | 6/12/90              |                              |                            | Waterfield, et al. |

## FOREIGN PATENT DOCUMENTS

| Examiner<br><u>Initials</u> | Document<br><u>Number</u> | Date   | Country | Date | Class /<br>Subclass | Translation<br>Yes      No |
|-----------------------------|---------------------------|--------|---------|------|---------------------|----------------------------|
| _____                       | WO 92/0524                | 4/2/92 |         | PCT  |                     |                            |

OTHER DOCUMENTS  
(Including Author, Title, Date, Pertinent Pages, etc.)Examiner  
Initials

\_\_\_\_\_ DEVELOPMENT, Volume 111, issued 1991, Christian, J., et al., "Xwnt-8, a Xenopus Wnt-1/int-1 related gene responsive to mesoderm-inducing growth factors, may play a role in ventral mesodermal patterning during embryogenesis," pp. 1045-1055.

\_\_\_\_\_ NATURE, Volume 361, issued February 11, 1993, Smith, W.C., et al., "Secreted noggin protein mimics the Spemann organizer in dorsalizing Xenopus mesoderm," pp. 547-549.

\_\_\_\_\_ CELL, Volume 67, issued November 15, 1991, Smith, W.C., and Harland, R.M., "Injected Xwnt-8 RNA Acts Early in Xenopus Embryos to Promote Formation of a Vegetal Dorsalizing Center", pp. 753-765.

\_\_\_\_\_ Brunet et al., Science, Vol. 280, pgs. 1455-57, 1998.

\_\_\_\_\_ Jackowski, A., British J. of Neurosurgery, Vol. 9, pgs. 303-317, 1995.

\_\_\_\_\_ Pepeu, G., et al., Drug Design and Delivery, Vol. 7, pgs. 1-10, 1990.


EXAMINER  
CONSIDERED

DATE

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Respectfully submitted,

By:

  
Valeta Gregg  
Reg. No. 35,127  
Patent Agent for Applicants  
Regeneron Pharmaceuticals, Inc.  
777 Old Saw Mill River Road  
Tarrytown, New York 10591  
(914) 345-7400